zepbound eli lilly - Search News

News

Texas AG sues Eli Lilly over alleged kickbacks

Texas Sues Eli Lilly For Alleged Kickback Scheme Involving Mounjaro, Zepbound

Texas Attorney General Ken Paxton has sued Eli Lilly, alleging the drugmaker offered illegal incentives to providers, leading to millions in improper Medicaid claims.

Houston Chronicle · 3d

Texas sues, accusing Eli Lilly of 'bribing' physicians to prescribe Zepbound, Mounjaro and other drugs

Paxton's office said the company supplied free nurses to help care for patients who received its drugs, as well as administrative support services that helped providers process insurance claims.

Reuters on MSN · 3d

Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications

"Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme," Texas Attorney General Ken Paxton said.

Eli Lilly raises UK price of obesity drug

Orforglipron: What to Know About Eli Lilly’s New Weight Loss Pill for Obesity

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials. The weight loss pill also significantly improved heart health markers like cholesterol and blood pressure.

Fast Company · 1d

Eli Lilly signs $1.3 billion deal with Superluminal to use AI to make obesity medicines

Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven platform.

The Financial Times · 1d

Eli Lilly raises UK price of obesity drug by up to 170% after Trump ‘freeloading’ gripe

Maker of popular Mounjaro treatment seeks to address White House concerns over higher medicine costs for Americans

8don MSN

Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

8don MSN

Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its ...

1d

5 Must-Read Analyst Questions From Eli Lilly’s Q2 Earnings Call

Eli Lilly delivered above-consensus results in the second quarter, surpassing Wall Street’s revenue and non-GAAP profit ...

4don MSN

Leerink Downgrades Eli Lilly and Company (LLY) to Market Perform From Outperform

Eli Lilly and Company (NYSE: LLY) is one of the top most profitable NYSE stocks to buy now. On August 7, Leerink downgraded ...

6d

Eli Lilly: Another Not-To-Miss Dip

Eli Lilly's stock dipped after drug trial results, but strong Q2 2025 earnings and market position make it a strong buy. Read ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results